Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 214

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Novel HER2–targeted therapies for HER2–positive metastatic breast cancer

Open access
Kunte, Siddharth, Abraham, Jame, Montero, Alberto J. · 2020 · Cancer

Abstract

Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% of all breast cancers. Before the development of HER2‐directed monoclonal antibodies, HER2–positive breast cancer was associated with a rather poor prognosis. With the advent of monoclonal HER2–targeting antibodies (trastuzumab and pertuzumab) and antibody‐drug conjugates (trastuzumab emtansine [T‐DM1] and trastuzumab deruxtecan), clinical outcomes for HER2–positive breast cancer have dramatically changed, and a greater proportion of patients in the nonmetastatic setting are cured. However, in the metastatic setting, resistance to anti‐HER2 treatments still remains a major therapeutic challenge, underscoring the importance of developing novel HER2‐directed therapies. Over the last year, there has been a dramatic shift in the current treatment paradigms for HER2–positive metastatic breast cancer, with recent U.S. Food and Drug Administration approvals of trastuzumab deruxtecan (DS‐8201), neratinib, and tucatinib in combination with trastuzumab and capecitabine. The authors summarize recent phase 3 data with novel HER2–targeted therapies as well as phase 1 and 2 data with other novel HER2–targeting agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.33102

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Kunte, S., Abraham, J., & Montero, A. J.
Venue
Cancer
Publisher
Wiley
Published
2020-07-28
Volume
126
Issue
19
Pages
4278-4288
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W3045680625
Cited by
214
References
7
FWCI
8.82
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.